Biology is plausible, but clinical translation has not been shown.
Editorial methodology
How to read the evidence
The Watchlist evaluates specific claims against source quality, clinical relevance, uncertainty, and safety or regulatory boundaries.
What the Watchlist is
A living evidence map for emerging therapies, drugs, peptides, neuromodulation, psychedelic-assisted therapy models, and longevity compounds.
What it is not
It is not medical advice, not a recommendation list, not a treatment guide, and not a guide to obtaining or using any product or therapy.
Medical and editorial boundary
Bioavailable is educational and evidence-focused. This Watchlist is not medical advice, not a diagnosis or treatment guide, not a recommendation list, and not guidance on obtaining or using any drug, peptide, supplement, or therapy. It does not provide dosing, cycles, stacks, sourcing, vendor, or administration instructions. Discuss medical decisions with a qualified clinician.
Evidence levels explained
Cell, animal, or non-human models dominate the evidence base.
Small or early human studies exist, usually with major uncertainty.
Controlled human data exist, but claim scope still matters.
Late clinical development or pivotal programs are being tracked.
Approved or cleared in defined contexts, not broad wellness proof.
Approved context plus substantial real-world or long-term use.
Evidence quality changes sharply by indication, product, or claim.
Safety, product identity, or regulatory status is central.
Source hierarchy
Highest-weight sources include FDA materials, DailyMed labels, ClinicalTrials.gov records, PubMed-indexed clinical trials, peer-reviewed journals, and major regulatory agencies. Sponsor releases are useful for tracking but must be labeled as sponsor releases.
How claims are evaluated
Each memo separates the claim being evaluated, signal so far, biggest unknown, safety/regulatory boundary, watch next, and evidence interpretation. A compound can have strong evidence for one claim and weak evidence for another.
Why product identity matters
Approved drug products, investigational trial products, compounded products, research-use products, and internet-market products should not be treated as interchangeable.
Why biomarkers are not outcomes
Biomarker movement can support biological plausibility, but it does not automatically show that people live longer, function better, avoid disease, or feel better.
Why approved use does not equal broad wellness proof
An approval or clearance applies to a defined product, population, indication, and evidence package. It does not validate unrelated wellness, longevity, or performance claims.
Why investigational does not equal available
Investigational status means a product or therapy is being studied. It does not mean it is approved, obtainable, safe for general use, or appropriate outside a trial.
Why compounding and research-use claims require caution
Compounding status, product characterization, impurities, labeling, and regulatory review can materially change the safety boundary. Vendor, seller, and sourcing pages are not acceptable evidence sources.
Update rules
Update a memo when the source of record changes, a new peer-reviewed trial appears, a regulatory action changes status, a major safety signal emerges, or a claim has been overstated and needs correction.